PT  - JOURNAL ARTICLE
AU  - J. C. Elkas
AU  - C. H. Holschneider
AU  - B. Katz
AU  - A. J. Li
AU  - R. Louie
AU  - K. F. Mcgonigle
AU  - J. S. Berek
TI  - The use of continuous infusion topotecan in persistent and recurrent ovarian cancer
AID  - 10.1136/ijgc-00009577-200303000-00006
DP  - 2003 Feb 01
TA  - International Journal of Gynecologic Cancer
PG  - 138--141
VI  - 13
IP  - 2
4099  - http://ijgc.bmj.com/content/13/2/138.short
4100  - http://ijgc.bmj.com/content/13/2/138.full
SO  - Int J Gynecol Cancer2003 Feb 01; 13
AB  - We retrospectively review our experience with continuous infusion topotecan for the treatment of persistent or recurrent ovarian cancer in this paper. Nine patients were identified who were treated at the University of California Los Angeles Medical Center between January 1997 and December 1999 using a 14–21 day continuous infusion schedule (0.3–0.7 mg/m2/d). Dose adjustments were performed for grade 3–4 toxicities and treatment was discontinued for persistent severe toxicity or progressive disease. Response to treatment was analyzed and stratified by platinum refractory, resistant, and sensitive disease. A total of 41 treatment cycles were given to nine patients with a median of five per patient (range 1–11). Median follow-up was 8 months. There were two partial responses (22%) and four patients had stable disease (44%), which included two patients with platinum-refractory tumors. No grade 3 or 4 hematologic toxicities were observed. However, two patients suffered grade 3 gastrointestinal toxicity during the first cycle leading to discontinuation of topotecan administration. There was no cumulative toxicity. Topotecan administered by continuous infusion demonstrated response rates comparable to other dosing schedules with minimal hematologic toxicity. Treatment of patients with persistent or recurrent ovarian cancer with continuous infusion topotecan warrants further investigation.